Gilead Sciences Drops 1.58% Amid Analyst Optimism, Policy Concerns

Gilead Sciences' stock price dropped by 1.58% in pre-market trading on April 7, 2025.

Gilead Sciences' stock price has been influenced by recent developments in the market. Goldman Sachs Group has increased their target price for Gilead Sciences from $85.00 to $96.00, maintaining a "neutral" rating. This adjustment reflects the company's performance and market outlook.

Additionally, Morgan Stanley analyst Terence Flynn has maintained a "buy" rating for Gilead Sciences, adjusting the target price from $123 to $130. Similarly, Wells Fargo analyst Mohit Bansal has also maintained a "buy" rating, increasing the target price from $120 to $140. These positive ratings from analysts indicate confidence in the company's future prospects.

However, there are concerns regarding potential funding cuts for HIV prevention by the Trump administration, which could impact drugmakers like Gilead Sciences. Such cuts could affect the company's revenue and market position, adding uncertainty to its stock performance.